

For immediate release

Seinäjoki, Finland, June 5, 2024

COMMUNIQUE FROM THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS IN EEVIA HEALTH PLC

The Extraordinary General Meeting of Shareholders of Eevia Health Plc, corp. reg. no 2825194-4 (the "Company") was held on June 5, 2024 in Seinäjoki, Finland, whereby the shareholders primarily resolved the following matters:

Authorizing the Board of Directors to decide on the issuance of shares, options, and other special rights

The Annual General Meeting authorized the Board of Directors to decide, in one or more transactions, on the issuance of shares, and the issuance of options and other special rights entitling to shares referred to in Chapter 10 Section 1 of the Companies Act.

The number of shares to be issued based on the authorization may in total amount to a maximum of 70 000 000 shares. The Board of Directors decides on all other terms and conditions of the issuances of shares and options and other special rights entitling to shares. The issuance of shares and options and other special rights entitling to shares may be carried out in deviation from the shareholders' preemptive rights (directed issue) if there is a weighty financial reason for the company. The authorization is valid until 30 June 2025.

Tel: +358 400 337 993

www.eeviahealth.com

Email: high5@eeviahealth.com

Business ID. nr.: 2825194-4

VAT nr.: FI28251944

For more information, please contact:

Stein Ulve, CEO

Email: stein@eeviahealth.com
Phone: +358 400 22 5967

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name <u>EEVIA</u>.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.

Tel: +358 400 337 993

www.eeviahealth.com

Email: high5@eeviahealth.com

Business ID. nr.: 2825194-4

VAT nr.: FI28251944